UNZA-UCLMS

For full list of publications available on the Pandora-ID website

Host-directed therapies for multidrug resistant tuberculosis. Zumla A, Maeurer M. Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S21-S22.

Short-term economic impact of the Zika virus outbreak. Macciocchi D, Lanini S, Vairo F, Zumla A, Figueiredo LT, Lauria FN, Strada G, Brouqui P, Puro V, Krishna S, Kremsner P, Scognamiglio P, Köhler C, Nicastri E, Di Caro A, Cieri RM, Ioannidis JP, Kobinger G, Burattini MN, Ippolito G. New Microbiol. 2016 Oct;39(4):287-289.

Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host-pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis. Zumla A, Otchere ID, Mensah GI, Asante-Poku A, Gehre F, Maeurer M, Bates M, Mwaba P, Ntoumi F, Yeboah-Manu D. Int J Infect Dis. 2016 Dec 12. 

The Middle East Respiratory Syndrome Coronavirus - A Continuing Risk to Global Health Security. Azhar EI, Lanini S, Ippolito G, Zumla A. Adv Exp Med Biol. 2016 Dec 14.

Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable? Centis R, D'Ambrosio L, Zumla A, Migliori GB. Int J Infect Dis. 2016 Dec 1.

Tuberculosis eradication versus control. Schito M, Hanna D, Zumla A.Int J Infect Dis. 2016 Nov 18. 

European policies in the management of tuberculosis among migrants. D'Ambrosio L, Centis R, Dara M, Solovic I, Sulis G, Zumla A, Migliori GB.Int J Infect Dis. 2016 Nov 9. 

WHO recommendations for multidrug-resistant tuberculosis - Authors' reply. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB. Lancet. 2016 Nov 5;388(10057):2234-2235.

Impact of Infectious Disease Epidemics on Tuberculosis Diagnostic, Management and Prevention Services: Experiences and Lessons from the 2014-2015 Ebola Virus Disease Outbreak in West Africa. Ansumana R, Keitell S, Roberts GM, Ntoumi F, Petersen E, Ippolito G, Zumla A. Int J Infect Dis. 2016 Nov 3.

Classifying new anti-TB drugs: rationale and future perspectives. Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Luna JA. Int J Infect Dis. 2016 Nov 3.

Applicability of the shorter 'Bangladesh regimen' in high MDR-TB settings. Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, Migliori GB. Int J Infect Dis. 2016 Nov 2.

Recent developments in the diagnosis and management of tuberculosis. Sulis G, Centis R, Sotgiu G, D'Ambrosio L, Pontali E, Spanevello A, Matteelli A, Zumla A, Migliori GB. NPJ Prim Care Respir Med. 2016 Nov 3;26:16078.

Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review. Wallis RS, Zumla A. Open Forum Infect Dis. 2016 Sep 7;3(3).

Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Fox GJ, Schaaf HS, Mandalakas A, Chiappini E, Zumla A, Marais BJ. Clin Microbiol Infect. 2016 Aug 31.

Infectious diseases epidemic threats and mass gatherings: refocusing global attention on the continuing spread of the Middle East Respiratory syndrome coronavirus (MERS-CoV). Zumla A, Alagaili AN, Cotten M, Azhar EI. BMC Med. 2016 Sep 7;14(1):132.

Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks. Edgar Simulundu, Aaron S. Mweene, Katendi Changula, Mwaka Monze, Elizabeth Chizema, Peter Mwaba, Ayato Takada, Guiseppe Ippolito, Francis Kasolo, Alimuddin Zumla, Matthew Bates Rev. Med. Virol. 2016; 1–9 PDF

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group. Eur Respir J. 2016 Sep 1.

Hepatitis C: Global Epidemiology and Strategies for Control. Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Clin Microbiol Infect. 2016 Aug 10.

Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis. Padayatchi N, Naidu N, Yende-Zuma N, OʼDonnell MR, Naidoo K, Augustine S, Zumla A, Loveday M.J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e1-7.

Burden of respiratory tract infections at post mortem in Zambian children. Bates M, Shibemba A, Mudenda V, Chimoga C, Tembo J, Kabwe M, Chilufya M, Hoelscher M, Maeurer M, Sinyangwe S, Mwaba P, Kapata N, Zumla A. BMC Med. 2016 Jul 1;14(1):99. PDF

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB. Lancet. 2016 Jun 18;387(10037):2486-7.

'Sample-in, answer-out'? Evaluation and comprehensive analysis of the Unyvero P50 pneumonia assay. Personne Y, Ozongwu C, Platt G, Basurto-Lozada P, Shamin M, Gant VA, Zumla A, Enne VI. Diagn Microbiol Infect Dis. 2016 Jun 14.

The annual Hajj pilgrimage - minimizing the risk of ill health in pilgrims from Europe and opportunity for driving the best prevention and health promotion guidelines. Shafi S, Dar O, Khan M, Khan M, Azhar EI, McCloskey B, Zumla A, Petersen E.
Int J Infect Dis. 2016 Jun 22

Pathogens, prejudice, and politics: the role of the global health community in the European refugee crisis. Khan MS, Osei-Kofi A, Omar A, Kirkbride H, Kessel A, Abbara A, Heymann D, Zumla A, Dar O. Lancet Infect Dis. 2016 Jun 20.

Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial. Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T, Ezechi OC, Yimer G, Yamuah LK, Medhin G, Connolly C, Rida W, Aderaye G, Zumla AI, Onyebujoh PC; 4FDC Study Group. PLoS One. 2016 Jun 20;11(6):

What is the experience from previous mass gathering events? Lessons for Zika virus and the Olympics 2016. Zumla A, Heymann D, McCloskey B, Bin Saeed AA, Dar O, Al Otabi B, Perlmann S, Gautret P, Roy N, Blumberg L, Azhar EI, Barbeschi M, Memish Z, Petersen E. Int J Infect Dis. 2016 Jun 15.

Hosting of mass gathering sporting events during the 2013-2016 Ebola virus outbreak in West Africa: experience from three African countries. Blumberg L, Regmi J, Endricks T, McCloskey B, Petersen E, Zumla A, Barbeschi M. Int J Infect Dis. 2016 Jun 15.

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. Zumla A, Rao M, Dodoo E, Maeurer M. BMC Med. 2016 Jun 15;14(1):89.

Zika virus and microcephaly: is the correlation causal or coincidental? Liuzzi G, Puro V, Lanini S, Vairo F, Nicastri E, Capobianchi MR, Di Caro A, Piacentini M, Zumla A, Ippolito G. New Microbiol. 2016 Apr;39(2):83-5.

Zika virus in saliva-New challenges for prevention of human to human transmission. Liuzzi G, Nicastri E, Puro V, Zumla A, Ippolito G. Eur J Intern Med. 2016 May 11.

Optimizing the benefits of pneumococcal vaccination in the Kingdom of Saudi Arabia. Azhar EI, Zumla A. Ann Thorac Med. 2016 Apr-Jun;11(2):91-2.

Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study. De Nardo P, Gentilotti E, Nguhuni B, Vairo F, Chaula Z, Nicastri E, Nassoro MM, Bevilacqua N, Ismail A, Savoldi A, Zumla A, Ippolito G. J Hosp Infect. 2016 Mar 11.

Exposed, but Not Protected: More Is Needed to Prevent Drug-Resistant Tuberculosis in Healthcare Workers and Students. von Delft A, Dramowski A, Sifumba Z, Mosidi T, Xun Ting T, von Delft D, Zumla A. Clin Infect Dis. 2016 May 15;62 Suppl 3:S275-80.

Active Screening and Surveillance in the United Kingdom for Middle East Respiratory Syndrome Coronavirus in returning travellers and pilgrims from the Middle East - a prospective descriptive study for the period 2013- 2015. Atabani SF, Wilson S, Overton-Lewis C, Workman J, Kidd IM, Petersen E, Zumla A, Smit E, Osman H. Int J Infect Dis. 2016 Apr 23.

To have Sepsis or to being Septic-is the difference between these clinical conditions important? Petersen E, Zumla A. Int J Infect Dis. 2016 Apr 23.

Understanding community-acquired respiratory tract infections: new concepts of disease pathogenesis and new management strategies. Niederman MS, Zumla A. Curr Opin Pulm Med. 2016 May;22(3):193-5.

Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. Agrati C, Castilletti C, Casetti R, Sacchi A, Falasca L, Turchi F, Tumino N, Bordoni V, Cimini E, Viola D, Lalle E, Bordi L, Lanini S, Martini F, Nicastri E, Petrosillo N, Puro V, Piacentini M, Di Caro A, Kobinger GP, Zumla A, Ippolito G, Capobianchi MR. Cell Death Dis. 2016 Mar 31;7:e2164.

Etiology, Antibiotic Resistance and Risk Factors for Neonatal Sepsis in a Large Referral Center in Zambia. Kabwe M, Tembo J, Chilukutu L, Chilufya M, Ngulube F, Lukwesa C, Kapasa M, Enne V, Wexner H, Mwananyanda L, Hamer DH, Sinyangwe S, Ahmed Y, Klein N, Maeurer M, Zumla A, Bates M. Pediatr Infect Dis J. 2016 Mar 30.

World TB Day 2016—advancing global tuberculosis control efforts.  Zumla A,  Oliver M, Sharma V, Masham S, Herbert N. Lancet Infect Dis. in press PDF

World TB Day 2016: reflections on the global TB emergency. Zumla A, Schito M, Chakaya J,
Marais B, Mwaba P, Migliori G.B, Hoelscher M, Maeurer M, Wallis R. Lancet Resp Med. in press PDF

Progress towards achieving global tuberculosis control: so near, yet so far. Zumla A, Davies P. The International Journal of Tuberculosis and Lung Disease. in press PDF

The International Journal of Tuberculosis and Lung Disease. Marais B, Outhred A, Zumla A. Int J Infect Dis. in press. PDF

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. 
Zumla A, Rao M, Wallis R, Kaufmann S, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M, for the Host-Directed Therapies Network consortium*Lancet Infect Dis. in press PDF

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Wallis R, Markus Maeurer, Peter Mwaba, Jeremiah Chakaya, Roxana Rustomjee, Giovanni Battista Migliori, Ben Marais, Marco Schito, Gavin Churchyard, Soumya Swaminathan, Michael Hoelscher, Alimuddin Zumla. Lancet Infect Dis. in press PDF

Tuberculosis and mass gatherings—opportunities for defining burden, transmission risk, and the optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. Alimuddin Zumla, Abdulaziz Bin Saeed, Badriah Alotaibi, Saber Yezli, Osman Dar, Kingsley Bieh, Matthew Bates, Tamara Tayeb, Peter Mwaba, Shuja Shafi , Brian McCloskey, Eskild Petersen, Esam I. Azhar. Int J Infect Dis. In press PDF

Host-directed therapies for antimicrobial resistant respiratory tract infections. Maeurer M, Rao M, Zumla A. Curr Opin Pulm Med. 2016 Mar 17.
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Eur Respir J. 2016 Mar 10. PDF

Zika virus and microcephaly: is the correlation, causal or coincidental? Liuzzi G, Puro V, Vairo F, Nicastri E, Capobianchi MR, Di Caro A, Piacentini M, Zumla A, Ippolito G. New Microbiol. 2016 Mar 10;39(2).

Taking forward the World TB Day 2016 theme "Unite to End Tuberculosis" for the WHO Africa Region. Ntoumi F, Kaleebu P, Macete E, Mfinanga S, Chakaya J, Yeboah-Manu D, Bates M, Mwaba P, Maeurer M, Petersen E, Zumla A. Int J Infect Dis. 2016 Mar 8. PDF

Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally. Zumla A, Goodfellow I, Kasolo F, Ntoumi F, Buchy P, Bates M, Azhar EI, Cotten M, Petersen E. Int J Infect Dis. 2016 Mar 4.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M. PLoS Med. 2016 Mar 2;13(3)

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Clin Infect Dis. 2016 Feb 16.

Tuberculosis and mass gatherings-opportunities for defining burden, transmission risk, and the optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. Zumla A, Saeed AB, Alotaibi B, Yezli S, Dar O, Bieh K, Bates M, Tayeb T, Mwaba P, Shafi S, McCloskey B, Petersen E, Azhar EI. Int J Infect Dis. 2016 Feb 9.

Coronaviruses — drug discovery and therapeutic options. Zumla A, Chan J, Ashar E, Hui D & Yuen KY. Nat Rev Drug Discov. 2016
Unexpected and Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games. Petersen E, Wilson ME, Touch S, McCloskey B, Mwaba P, Bates M, Dar O, Mattes F, Kidd M, Ippolito G, Azhar EI, Zumla A. Int J Infect Dis. 2016 Feb 4.

The Prevalence of Tuberculosis in Zambia: Results from the First National TB Prevalence Survey, 2013-2014. Kapata N, Chanda-Kapata P, Ngosa W, Metitiri M, Klinkenberg E, Kalisvaart N, Sunkutu V, Shibemba A, Chabala C, Chongwe G, Tembo M, Mulenga L, Mbulo G, Katemangwe P, Sakala S, Chizema-Kawesha E, Masiye F, Sinyangwe G, Onozaki I, Mwaba P, Chikamata D, Zumla A, Grobusch MP.
PLoS One. 2016 Jan 15;11(1):

The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis. Bates M, Zumla A. Expert Rev Mol Diagn. 2016 Mar;16(3):307-22.

Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games. Petersen E, Wilson ME, Touch S, McCloskey B, Mwaba P, Bates M, Dar O, Mattes F, Kidd M, Ippolito G, Azhar EI, Zumla A. Int J Infect Dis. 2016 Mar;44:11-5.

Exploring the evidence base for national and regional policy interventions to combat resistance. Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, Littmann J, Rweyemamu M, Buckley EJ, Shahid M, Kock R, Li HL, Giha H, Khan M, So AD, Bindayna KM, Kessel A, Pedersen HB, Permanand G, Zumla A, Røttingen JA, Heymann DL. Lancet. 2016 Jan 16;387(10015):285-95.

IFN-γ Release Assays for Risk Assessment in Contacts of Patients with Tuberculosis in Low-Burden European Countries. Zumla A, Maeurer M. Am J Respir Crit Care Med. 2015 May 15;191(10):1101-1103.

Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lanini S, Zumla A, Ioannidis JP, Caro AD, Krishna S, Gostin L, Girardi E, Pletschette M, Strada G, Baritussio A, Portella G, Apolone G, Cavuto S, Satolli R, Kremsner P, Vairo F, Ippolito G.

Lessons for Tuberculosis from scrutiny of HIV/AIDS and Malaria UK Parliamentary Questions. Oliver M, Craig GM, Zumla A. Int J Infect Dis. 2015 Mar;32:191-195.

Why healthcare workers are sick of TB. von Delft A, Dramowski A, Khosa C, Kotze K, Lederer P, Mosidi T, Peters JA, Smith J, van der Westhuizen HM, von Delft D, Willems B, Bates M, Craig G, Maeurer M, Marais BJ, Mwaba P, Nunes EA, Nyirenda T, Oliver M, Zumla A. Int J Infect Dis. 2015 Mar;32:147-51

Perspectives on tuberculosis in pregnancy. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Int J Infect Dis. 2015 Mar;32:124-7. 

The social context of tuberculosis treatment in urban risk groups in the United Kingdom: a qualitative interview study. Craig GM, Zumla A. Int J Infect Dis. 2015 Mar;32:105-10. 

Imaging in tuberculosis. Skoura E, Zumla A, Bomanji J. Int J Infect Dis. 2015 Mar;32:87-93. 

New tuberculosis diagnostics and rollout. McNerney R, Cunningham J, Hepple P, Zumla A. Int J Infect Dis. 2015 Mar;32:81-86. 

Surgical Treatment of Complications of Pulmonary Tuberculosis, including Drug-Resistant Tuberculosis. Madansein R, Parida S, Padayatchi N, Singh N, Master I, Naidu K, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:61-67. 

Tackling the Tuberculosis Epidemic in sub-Saharan Africa - unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Zumla A, Petersen E, Nyirenda T, Chakaya J. Int J Infect Dis. 2015 Mar;32:46-9. 

Cellular therapy in Tuberculosis. Parida SK, Madansein R, Singh N, Padayatchi N, Master I, Naidu K, Zumla A, Maeurer M. Int J Infect Dis. 2015 Mar;32:32-8.

Host-directed therapies for tuberculous pericarditis. Zumla A, Maeurer M, Moll G, Mayosi BM. Int J Infect Dis. 2015 Mar;32:30-1. 

Frequency of Mycobacterium tuberculosis-specific CD8+ T-cells in the course of anti-tuberculosis treatment. Axelsson-Robertson R, Rao M, Loxton AG, Walzl G, Bates M, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:23-9. 

Mycobacterium tuberculosis-specific and MHC class I-restricted CD8+ T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosis. Axelsson-Robertson R, Ju JH, Kim HY, Zumla A, Maeurer M. Int J Infect Dis. 2015 Mar;32:13-22. 

Commemorating world tuberculosis day 2015. Zumla A, Maeurer M, Marais B, Chakaya J, Wejse C, Lipman M, McHugh TD, Petersen E. Int J Infect Dis. 2015 Mar;32:1-4. 

Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Lancet Respir Med. 2015 Mar;3(3):220-34.

Respiratory tract infections in community and healthcare settings: epidemiological, diagnostic and management challenges. Zumla A, Niederman MS. Curr Opin Pulm Med. 2015 Mar 16.

Emerging respiratory tract viral infections. Hui DS, Zumla A. Curr Opin Pulm Med. 2015 Mar 11. 

Impact of the Xpert MTB/RIF diagnostic test for tuberculosis in countries with a high burden of disease. McNerney R, Zumla A. Curr Opin Pulm Med. 2015 Mar 11.

Host-directed therapy: tuberculosis vaccine development. Rao M, Zumla A, Maeurer M. Lancet Respir Med. 2015 Feb 25. 

Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases. Bates M, Marais BJ, Zumla A. Cold Spring Harb Perspect Med. 2015 Feb 6. pii: a017889.

Clinical Aspects of Adult Tuberculosis. Loddenkemper R, Lipman M, Zumla A. Cold Spring Harb Perspect Med. 2015 Feb 6. pii: a017848.

Middle East respiratory syndrome in the shadow of Ebola. Zumla A, Perlman S, McNabb SJ, Shaikh A, Heymann DL, McCloskey B, Hui DS. Lancet Respir Med. 2015 Jan 12. pii: S2213-2600(14)70316-9. doi: 10.1016/S2213-2600(14)70316-9. 

TB-HAART trial - Authors' reply. Mfinanga SG, Kirenga BJ, Chanda DM, Connolly C, Mwaba P, Joloba M, Zumla A; TB-HAART Study Group. Lancet Infect Dis. 2015 Jan;15(1):15-6. doi: 10.1016/S1473-3099(14)71051-5.

The WHO 2014 Global tuberculosis report-further to go. Zumla A, George A, Sharma V, Herbert RH; Baroness Masham of Ilton, Oxley A, Oliver M. Lancet Glob Health. 2015 Jan;3(1):e10-2. doi: 10.1016/S2214-109X(14)70361-4. 

Genesis of EDCTP2. Zumla A, Makanga M, Nyirenda T, Beattie P, Olesen OF, Breugelmans JG, Aklillu E, Corrah T, Mgone C. Lancet Infect Dis. 2015 Jan;15(1):11-3.

Prevalence and Risk Factors for Betaherpesvirus DNAemia in Children >3 Weeks and <2 Years of Age Admitted to a Large Referral Hospital in Sub-Saharan Africa. Tembo J, Kabwe M, Chilukutu L, Chilufya M, Mwaanza N, Chabala C, Zumla A, Bates M. Clin Infect Dis. 2015 Feb 1;60(3):423-31

An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in jeddah and riyadh, kingdom of saudi arabia, 2014. Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, HajOmar W, Landt O, Assiri A, Eckerle I, Al Shangiti A, Al-Tawfiq JA, Albarrak A, Zumla A, Rambaut A, Memish ZA. Clin Infect Dis. 2015 Feb 1;60(3):369-77.

The neglected global burden of tuberculosis in pregnancy. Zumla A, Bates M, Mwaba P. The Lancet Global Health, Volume 2, Issue 12, Pages e675 - e676, December 2014

The host battles drug-resistant tuberculosis. Maeurer M, Zumla A. Sci Transl Med. 2014 Nov 19;

Neonatal Sepsis and Antibiotic Resistance in Developing Countries. Bates M, Kabwe M, Zumla A. Paed. Infect. Dis. J. Oct 2014 10.1097/INF.0000000000000388 PDF

Clinical features, microbiology and surgical outcomes of infective endocarditis: a 13-year study from a UK tertiary cardiothoracic referral centre. Marks DJ, Hyams C, Koo CY, Pavlou M, Robbins J, Koo CS, Rodger G, Huggett JF, Yap J, Macrae MB, Swanton RH, Zumla AI, Miller RF. QJM. 2014 Sep 15.

Pregnancy and Infection. Zumla A, Bates M, Maeurer M. N Engl J Med. 2014 Sep 11;371(11):1075-1077. PDF

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. N Engl J Med. 2014 Oct 23;371(17):

Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfiq JA, Denning DW, Hayden FG, Hui DS. Lancet Infect Dis. 2014 Sep 1 PDF

Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread. McCloskey B, Dar O, Zumla A, Heymann DL. Lancet Infect Dis. 2014 Sep 1 PDF

Emerging viral respiratory tract infections-environmental risk factors and transmission. Gautret P, Gray GC, Charrel RN, Odezulu NG, Al-Tawfiq JA, Zumla A, Memish ZA. Lancet Infect Dis. 2014 Sep 1 PDF

Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections-needs, advances, and future prospects. Zumla A, Al-Tawfiq JA, Enne VI, Kidd M, Drosten C, Breuer J, Muller MA, Hui D, Maeurer M, Bates M, Mwaba P, Al-Hakeem R, Gray G, Gautret P, Al-Rabeeah AA, Memish ZA, Gant V. Lancet Infect Dis. 2014 Sep 1 PDF

Emerging respiratory tract infections. Zumla A, Hui DS, Al-Tawfiq JA, Gautret P, McCloskey B, Memish ZA. Lancet Infect Dis. 2014 Sep 1 PDF

Surveillance for emerging respiratory viruses. Al-Tawfiq JA, Zumla A, Gautret P, Gray GC, Hui DS, Al-Rabeeah AA, Memish ZA. Lancet Infect Dis. 2014 Sep 1 PDF

Transmission of MERS-coronavirus in household contacts. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, Madani H, Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak AM, Al-Tawfiq JA, Zumla AI, Memish ZA. N Engl J Med. 2014 Aug 28;371(9):828-35.

Travel implications of emerging coronaviruses: SARS and MERS-CoV. Al-Tawfiq JA, Zumla A, Memish ZA. Travel Med Infect Dis. 2014 Jul 9.

Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers. Al-Tawfiq JA, Zumla A, Memish ZA. Curr Opin Infect Dis. 2014 Oct;27(5):411-7

Epidemiology and clinical management of Legionnaires' disease. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, Lortholary O, Zumla A, Abubakar I. Lancet Infect Dis. 2014 Jun 23.

'Complex' but coping: experience of symptoms of tuberculosis and health care seeking behaviours - a qualitative interview study of urban risk groups, London, UK. Craig GM, Joly LM, Zumla A. BMC Public Health. 2014 Jun 18;14(1):618.

Euro 2012 European Football Championship Finals: planning for a health legacy. Smallwood CA, Arbuthnott KG, Banczak-Mysiak B, Borodina M, Coutinho AP, Payne-Hallström L, Lipska E, Lyashko V, Miklasz M, Miskiewicz P, Nitzan D, Pokanevych I, Posobkiewicz M, Rockenschaub G, Sadkowska-Todys M, Sinelnik S, Smiley D, Tomialoic R, Yurchenko V, Memish ZA, Heymann D, Endericks T, McCloskey B, Zumla A, Barbeschi M. Lancet. 2014 May 20.

Mass gatherings medicine: international cooperation and progress. Memish ZA, Zumla A, McCloskey B, Heymann D, Al Rabeeah AA, Barbeschi M, Horton R. Lancet. 2014 May 20.

Hajj: infectious disease surveillance and control. Memish ZA, Zumla A, Alhakeem RF, Assiri A, Turkestani A, Al Harby KD, Alyemni M, Dhafar K, Gautret P, Barbeschi M, McCloskey B, Heymann D, Al Rabeeah AA, Al-Tawfiq JA. Lancet. 2014 May 20.

Infection control and MERS-CoV in health-care workers. Zumla A, Hui DS. Lancet. 2014 May 20.

London 2012 Olympic and Paralympic Games: public health surveillance and epidemiology. McCloskey B, Endericks T, Catchpole M, Zambon M, McLauchlin J, Shetty N, Manuel R, Turbitt D, Smith G, Crook P, Severi E, Jones J, Ibbotson S, Marshall R, Smallwood CA, Isla N, Memish ZA, Al-Rabeeah AA, Barbeschi M, Heymann DL, Zumla A. Lancet. 2014 May 20

Respiratory Tract Samples, Viral Load and Genome Fraction Yield in patients with Middle East Respiratory Syndrome. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, Alsubaie S, Al-Rabeeah AA, Hajomar WH, Hussain R, Kheyami AM, Almutairi A, Azhar EI, Drosten C, Watson SJ, Kellam P, Cotten M, Zumla A. J Infect Dis. 2014 May 15.

Middle East Respiratory Syndrome Corona virus, MERS-CoV. Conclusions from the 2ndScientific Advisory Board Meeting of the WHO Collaborating Center for Mass Gathering Medicine, Riyadh. Memish ZA, Al-Tawfiq J, Drosten C, Assiri A, Alhakeem R, Albarrak A, Yezli S, Almasri M, Zumla A, Petersen E. Int J Infect Dis. 2014 May 10

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O, Connolly C, Kapotwe V, Muwonge C, Massaga J, Sinkala E, Kohi W, Lyantumba L, Nyakoojo G, Luwaga H, Doulla B, Mzyece J, Kapata N, Vahedi M, Mwaba P, Egwaga S, Adatu F, Pym A, Joloba M, Rustomjee R, Zumla A, Onyebujoh P. Lancet Infect Dis. 2014 May 2.

Totally-drug resistant tuberculosis and adjunct therapies. Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, Keshavjee S, Andersson J, Zumla A, Maeurer M. J Intern Med. 2014 May 8.

Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. Lancet Respir Med. 2014 Apr;2(4):301-320.

Totally-drug-resistant tuberculosis: hype versus hope. Maeurer M, Schito M, Zumla A. Lancet Respir Med. 2014 Apr;2(4):256-7.

Inflammation and tuberculosis: host-directed therapies. Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson-Robertsson R, Doherty M, Andersson J, Maeurer M. J Intern Med. 2014 Apr 10.

Congenital cytomegalovirus infections in sub-Saharan Africa - a neglected and growing problem. Bates M, Tembo J, Zumla A. Trop Med Int Health. 2014 Apr 10. PDF

Community Case Clusters of Middle East Respiratory Syndrome Coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: A Descriptive Genomic study. Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF, Assiri A, Rabeeah AA, Al-Tawfiq JA. Int J Infect Dis. 2014 Mar 31.

Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gram-negative bacteria: is it time for a paradigm shift? Tuite N, Reddington K, Barry T, Zumla A, Enne V. J Antimicrob Chemother. 2014 Mar 27. 

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines. Zumla AI, Schito M, Maeurer M. Lancet Infect Dis. 2014 Apr;14(4):267-9.

WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Zumla A, George A, Sharma V, Herbert N, Baroness Masham of Ilton. Lancet. 2013 Nov 30;382(9907):1765-7. PDF

Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Enne VI, Personne Y, Grgic L, Gant V, Zumla A. Curr Opin Pulm Med. 2014 Mar 7. 

Spread, circulation, and evolution of the middle East respiratory syndrome coronavirus. Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, Albarrak A, Barry M, Shibl A, Alrabiah FA, Hajjar S, Balkhy HH, Flemban H, Rambaut A, Kellam P, Memish ZA. MBio. 2014 Feb 18;5(1). 

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, Skrahina A, Zumla A, Maeurer MJ. Lancet Respir Med. 2014 Feb;2(2):108-22. 

Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Al-Rabeeah AA, Assiri A, Alhakeem RF, Alrabiah FA, Al Hajjar S, Albarrak A, Flemban H, Balkhy H, Barry M, Alhassan S, Alsubaie S, Zumla A. Clin Microbiol Infect. 2014 Jan 24. 

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Lancet Respir Med. 2013 Aug;1(6):462-70.

Tuberculosis drug discovery in the post-post-genomic era. Lechartier B, Rybniker J, Zumla A, Cole ST. EMBO Mol Med. 2014 Jan 8.

Rapid diagnostics urgently needed for killer infections. Zumla A, Gant V, Bates M, Mwaba P, Maeurer M, Memish ZA. Lancet Respir Med. 2013 Jun;1(4):284-5.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Lancet Respir Med. 2013 Aug;1(6):462-70. 

High rates of congenital cytomegalovirus (CMV) infections linked with maternal HIV infection among neonatal admissions at a large referral centre in sub-Saharan Africa. Mwaanza N, Chilukutu L, Tembo J, Kabwe M, Musonda K, Kapasa M, Chabala C, Sinyangwe S, Mwaba P, Zumla A, Bates M. Clin Infect Dis 2013 Nov 22 PDF

Advancing Priority Research on the Middle East Respiratory Syndrome Coronavirus. Hui DF, Zumla A. J Infect Dis. 2013 Nov 11

Reversing the tide of the UK tuberculosis epidemic. Zenner D, Zumla A, Gill P, Cosford P, Abubakar I. Lancet. 2013 Oct 19;382(9901):1311-2. PDF

How great is the risk of Middle East respiratory syndrome coronavirus to the global population?

Trends in Childhood Tuberculosis in Zambia: A Situation Analysis. Kapata N, Chanda-Kapata P, O'Grady J, Bates M, Mwaba P, Janssen S, Marais B, Cobelens F, Grobusch M, Zumla A. J Trop Pediatr. 2012 Dec 12. [Epub ahead of print]

HIV Case Notification Rates in the Kingdom of Saudi Arabia over the Past Decade (2000-2009). Mazroa MA, Kabbash IA, Felemban SM, Stephens GM, Al-Hakeem RF, Zumla AI, Memish ZA. PLoS One. 2012;7(9)

Travel medicine. Zumla A, Behrens RH, Memish ZA. Infect Dis Clin North Am. 2012 Sep;26(3)

Eosinophilia in the returning traveler. Ustianowski A, Zumla A. Infect Dis Clin North Am. 2012 Sep;26(3):781-9

New global estimates of malaria deaths. Bates M, O'Grady J, Mudenda V, Shibemba A, Zumla A. Lancet. 2012 Aug 11;380(9841):560-1

Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. Bates M, O'Grady J, Mwaba P, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Rachow A, Clowes P, Maeurer M, Hoelscher M, Zumla A. PLoS One. 2012;7(7):e40774. Epub 2012 Jul 27. PDF

Leprosy trends in Zambia 1991-2009. Kapata N, Chanda-Kapata P, Grobusch MP, O'Grady J, Bates M, Mwaba P, Zumla A. Trop Med Int Health. 2012 Jul 29

Evaluation of the Xpert MTB/RIF Assay at a Tertiary Care Referral Hospital in a Setting Where Tuberculosis and HIV Infection Are Highly Endemic. O'Grady J, Bates M, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Maeurer M, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A. Clin Infect Dis. 2012 Nov;55(9):1171-8 PDF

Mass gatherings medicine and global health security. Al Rabeeah A, Memish ZA, Zumla A, Shafi S, McCloskey B, Moolla A, Barbeschi M, Heymann D, Horton R. Lancet. 2012 Jul 7;380(9836):3-4

Tuberculosis trends in Saudis and non-Saudis in the Kingdom of Saudi Arabia--a 10 year retrospective study (2000-2009). Abouzeid MS, Zumla AI, Felemban S, Alotaibi B, O'Grady J, Memish ZA. PLoS One. 2012;7(6):e39478. Epub 2012 Jun 20

Diagnosis of extrapulmonary tuberculosis using the Xpert(®) MTB/RIF assay. Lawn SD, Zumla AI. Expert Rev Anti Infect Ther. 2012 Jun;10(6):631-5

The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity? Zumla A. Int J Tuberc Lung Dis. 2012;16(3):285-6

Preface: tropical diseases. Zumla A, Keiser J. Infect Dis Clin North Am. 2012 Jun;26(2):xv-xvii. Epub 2012 Apr 4

Tropical diseases: definition, geographic distribution, transmission, and classification. Zumla A, Ustianowski A. Infect Dis Clin North Am. 2012 Jun;26(2):195-205. Epub 2012 Apr 2

Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections. Ferrara G, Zumla A, Maeurer M. Am J Med. 2012 Oct;125(10

Scaling up interventions to achieve global tuberculosis control: progress and new developments. Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A. Lancet. 2012 May 19;379(9829):1902-13. Review. Erratum in: Lancet. 2012 Jun 16;379(9833):2242.

SeekTB, a two-stage multiplex real-time-PCR-based method for differentiation of the Mycobacterium tuberculosis complex. Reddington K, Zumla A, Bates M, van Soolingen D, Niemann S, Barry T, O'Grady J. J Clin Microbiol. 2012 Jul;50(7):2203-6. doi: 10.1128/JCM.00718-12. Epub 2012 May 2.

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditui L, Atun R, Zumla A. J Infect Dis. 2012 May 15;205 Suppl 2:S147-58

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar J, Anger H, Caminero J, Castiglia P, De Lorenzo S, Ferrara G, Koh W, Schecter G, Shim T, Singla R, Skrahina A, Spanevello A, Udwadia Z, Villar M, Zampogna E, Zellweger J, Zumla A, Migliori GB. Eur Respir J. 2012 Apr 10.

Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Geldmacher C, Zumla A, Hoelscher M. Curr Opin HIV AIDS. 2012 May;7(3):268-75.

Scale-up of TB and HIV programme collaborative activities in Zambia - a 10-year review. Kapata N, Chanda-Kapata P, Grobusch MP, O'Grady J, Schwank S, Bates M, Jansenn S, Mwinga A, Cobelens F, Mwaba P, Zumla A.Trop Med Int Health. 2012 Jun;17(6):760-6

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. J Infect Dis. 2012 May 15;205 Suppl 2:S228-40.

European union standards for tuberculosis care. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D. Eur Respir J. 2012 Apr;39(4):807-19.

Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. Zumla A, Blasi F, Raviglione M. Eur Respir J. 2012 Apr;39(4):802-4.

Adjunct immunotherapies for tuberculosis. Uhlin M, Andersson J, Zumla A, Maeurer M. J Infect Dis. 2012 May 15;205 Suppl 2:S325-34. Epub 2012 Mar 29.

Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009. Akachi Y, Zumla A, Atun R. J Infect Dis. 2012 May 15;205 Suppl 2:S284-92

Innovative trial designs are practical solutions for improving the treatment of tuberculosis. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M. J Infect Dis. 2012 May 15;205 Suppl 2:S250-7

Global fund financing of tuberculosis services delivery in prisons. Lee D, Lal SS, Komatsu R, Zumla A, Atun R. J Infect Dis. 2012 May 15;205 Suppl 2:S274-83. 

Controversies and unresolved issues in tuberculosis prevention and control: a low-burden-country perspective. Abubakar I, Stagg HR, Cohen T, Mangtani P, Rodrigues LC, Pimpin L, Watson JM, Squire SB, Zumla A. J Infect Dis. 2012 May 15;205 Suppl 2:S293-300.

Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. Mudenda V, Lucas S, Shibemba A, O'Grady J, Bates M, Kapata N, Schwank S, Mwaba P, Atun R, Hoelscher M, Maeurer M, Zumla A. J Infect Dis. 2012 May 15;205 Suppl 2:S340-6. 

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9.

The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. J Infect Dis. 2012 May 15;205 Suppl 2:S301-15.

Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. Zumla A, Atun R, Maeurer M, Kim PS, Jean-Philippe P, Hafner R, Schito M. J Infect Dis. 2012 May 15;205 Suppl 2:S141-6.

A sustainable agenda for tuberculosis control and research. Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A.Lancet. 2012 Mar 24;379(9821):1077-8.

Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders. Haroon A, Zumla A, Bomanji J. Clin Infect Dis. 2012 May;54(9):1333-41. 

Surgery and tuberculosis.Cummings I, O'Grady J, Pai V, Kolvekar S, Zumla A.Curr Opin Pulm Med. 2012 May;18(3):241-5.

Operational research and MDG tuberculosis control targets. Zumla A, Cobelens F. Lancet Infect Dis. 2012 Apr;12(4):262-3. 

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs. Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, Maeurer M, Zumla A. Curr Opin Pulm Med. 2012 May;18(3):233-40.

Advancing the development of tuberculosis therapy. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Nat Rev Drug Discov. 2012 Mar 1;11(3):171-2.

Analogies and metaphors in clinical medicine.Masukume G, Zumla A. Clin Med. 2012 Feb;12(1):55-6.

Killer respiratory tract infections: time to turn the tide. Zumla A.Curr Opin Pulm Med. 2012 May;18(3):173-4. 

Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus. Ahmed RK, Rohava Z, Balaji KN, Hoffner SE, Gaines H, Magalhaes I, Zumla A, Skrahina A, Maeurer MJ. BMC Infect Dis. 2012 Feb 15;12:41.

Thoracic empyema: a 12-year study from a UK tertiary cardiothoracic referral centre.Marks DJ, Fisk MD, Koo CY, Pavlou M, Peck L, Lee SF, Lawrence D, Macrae MB, Wilson AP, Brown JS, Miller RF, Zumla AI. PLoS One. 2012;7(1):e30074. Epub 2012 Jan 20.

Tuberculosis in prisons: anatomy of global neglect. O'Grady J, Maeurer M, Atun R, Abubakar I, Mwaba P, Bates M, Kapata N, Ferrara G, Hoelscher M, Zumla A. Eur Respir J. 2011 Oct;38(4):752-4.

Tackling the spread of drug-resistant tuberculosis in Europe. Abubakar I, Dara M, Manissero D, Zumla A. Lancet. 2012 Jan 28;379(9813)

Tuberculosis in prisons: anatomy of global neglect. O'Grady J, Maeurer M, Atun R, Abubakar I, Mwaba P, Bates M, Kapata N, Ferrara G, Hoelscher M, Zumla A. Eur Respir J. 2011 Oct;38(4):752-4. 

Tackling the spread of drug-resistant tuberculosis in Europe. Abubakar I, Dara M, Manissero D, Zumla A. Lancet. 2012 Jan 28;379(9813):e21-3. doi: 10.1016/S0140-6736(11)61428-1. Epub 2011 Sep 14. No abstract available. 

Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Migliori GB, Sotgiu G, Blasi F, Zumla A, Loddenkemper R, Raviglione MC, Abubakar I, Sandgren A, Manissero D. Eur Respir J. 2011 Sep;38(3):493-5. 

Screening of immigrants in the UK for latent tuberculosis. McNerney R, Ferrara G, O'Grady J, Maeurer M, Zumla A. Expert Rev Respir Med. 2011 Aug;5(4):483-6.

Xpert MTB/RIF test for tuberculosis. Ferrara G, O'Grady J, Zumla A, Maeurer M. Lancet. 2011 Aug 6;378(9790):482; author reply 482-3. 

Xpert MTB/RIF test for tuberculosis. Salvo F, Sadutshang TD, Migliori GB, Zumla A, Cirillo DM. Lancet. 2011 Aug 6;378(9790):481-2

Tuberculosis in the UK--time to regain control. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A. BMJ. 2011 Jul 29;343:d4281.

Trends of Zambia's tuberculosis burden over the past two decades. Kapata N, Chanda-Kapata P, O'Grady J, Schwank S, Bates M, Mukonka V, Zumla A, Mwaba P. Trop Med Int Health. 2011 Nov;16(11):1404-9. 

Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, Ntinginya EN, O'Grady J, Huggett J, Dheda K, Boehme C, Perkins M, Saathoff E, Hoelscher M. PLoS One. 2011;6(6):e20458.

A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis? Ferrara G, Parida SK, Zumla A, Richeldi L, Maeurer M. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1732. No abstract available. 

Tuberculosis in prisons in sub-Saharan Africa--a potential time bomb. O'Grady J, Mwaba P, Bates M, Kapata N, Zumla A. S Afr Med J. 2011 Feb;101(2):107-8. 

The health of prisoners. O'Grady J, Mwaba P, Zumla A. Lancet. 2011 Jun 11;377(9782):2001. 

Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Mwaba P, McNerney R, Grobusch MP, O'Grady J, Bates M, Kapata N, Maeurer M, Zumla A. Trop Med Int Health. 2011 Jul;16(7):819-27.

Immunological biomarkers of tuberculosis. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Nat Rev Immunol. 2011 May;11(5):343-54.

Tuberculosis. Lawn SD, Zumla AI. Lancet. 2011 Jul 2;378(9785):57-72. 

New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. O'Grady J, Maeurer M, Mwaba P, Kapata N, Bates M, Hoelscher M, Zumla A. Curr Opin Pulm Med. 2011 May;17(3):134-41.

Pulmonary infections: 'le terrain est tout, le microbe n'est rien'. Zumla A. Curr Opin Pulm Med. 2011 May;17(3):131-3.

Combined PET and X-ray computed tomography imaging in pulmonary infections and inflammation. Bomanji J, Almuhaideb A, Zumla A. Curr Opin Pulm Med. 2011 May;17(3):197-205. 

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, O'Grady J, Bates M, Dheda K, Hoelscher M, Grange J. Trop Med Int Health. 2011 Jan;16(1):79-83. 

New tools for achieving tuberculosis control: progress and reflexion. Zumla A, Yew WW. Int J Tuberc Lung Dis. 2011 Mar;15(3):285-6. 

Randomised, placebo-controlled trial to evaluate co-trimoxazole to reduce mortality and morbidity in HIV-infected post-natal women in Zambia (TOPAZ). Nunn AJ, Mwaba PB, Chintu C, Crook AM, Darbyshire JH, Ahmed Y, Zumla AI. Trop Med Int Health. 2011 Apr;16(4):518-26. 

Modulation of cell death by M. tuberculosis as a strategy for pathogen survival. Abebe M, Kim L, Rook G, Aseffa A, Wassie L, Zewdie M, Zumla A, Engers H, Andersen P, Doherty TM. Clin Dev Immunol. 2011;2011:678570. 

Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control. O'Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, Ferrara G, Maeurer M, Zumla A.Tuberculosis (Edinb). 2011 Mar;91(2):173-8. 

Mycotic aneurysms: a case report, clinical review and novel imaging strategy. Fisk M, Peck LF, Miyagi K, Steward MJ, Lee SF, Macrae MB, Morris-Jones S, Zumla AI, Marks DJ. QJM. 2012 Feb;105(2):181-8. 

Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, Dheda K. PLoS One. 2010 Dec 22;5(12):e15664. 

The white plague returns to London--with a vengeance. Zumla A. Lancet. 2011 Jan 1;377(9759):10-1. 

Is the eradication of tuberculosis 'yesterday's ambition' or 'tomorrow's triumph'? Zumla A, Grange JM. Clin Med. 2010 Oct;10(5):450-3.

Tuberculosis control is crucial to achieve the MDGs. Atun R, Raviglione M, Marais B, Zumla A. Lancet. 2010 Sep 18;376(9745):940-1. 

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Jarand J, Shean K, O'Donnell M, Loveday M, Kvasnovsky C, Van der Walt M, Adams S, Willcox P, O'Grady J, Zumla A, Dheda K. Trop Med Int Health. 2010 Oct;15(10):1179-84. 

Pneumocystis jirovecii in pleural infection: a nucleic acid amplification study. Wrightson JM, Rahman NM, Novak T, Huggett JF, Maskell NA, Zumla A, Miller RF, Davies RJ. Thorax. 2011 May;66(5):450-1. 

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Lancet Infect Dis. 2010 Sep;10(9):621-9. 

Extensively drug-resistant tuberculosis: epidemiology and management challenges. Dheda K, Warren RM, Zumla A, Grobusch MP. Infect Dis Clin North Am. 2010 Sep;24(3):705-25. 

Emerging respiratory infections in the 21st century. Preface. Zumla A, Yew WW, Hui DS. Infect Dis Clin North Am. 2010 Sep;24(3):xiii-xvi.

Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O'Grady J, Hoelscher M, Zumla A. Trop Med Int Health. 2010 Sep;15(9):1052-66. 

Research capacity strengthening in African countries. Mwaba P, Bates M, Green C, Kapata N, Zumla A. Lancet. 2010 May 29;375(9729):1874. 

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C. Lancet. 2010 May 22;375(9728):1798-807. 

Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, El-Sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A. Lancet. 2010 Jun 19;375(9732):2179-91. 

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Lancet. 2010 May 29;375(9729):1920-37. 

Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Rakotosamimanana N, Raharimanga V, Andriamandimby SF, Soares JL, Doherty TM, Ratsitorahina M, Ramarokoto H, Zumla A, Huggett J, Rook G, Richard V, Gicquel B, Rasolofo-Razanamparany V; VACSEL/VACSIS Study Group. Clin Vaccine Immunol. 2010 Jul;17(7):1094-103. 

World TB Day 2010: eradicating tuberculosis in sub-Saharan Africa needs effective and committed north-south partnerships. Marais B, Hoelscher M, Mwaba P, Dheda K, Zumla A.S Afr Med J. 2010 Mar 8;100(3):153-4.

Feasibility and diagnostic utility of antigen-specific interferon-gamma responses for rapid immunodiagnosis of tuberculosis using induced sputum. Cashmore TJ, Peter JG, van Zyl-Smit RN, Semple PL, Maredza A, Meldau R, Zumla A, Nurse B, Dheda K. PLoS One. 2010 Apr 28;5(4):e10389. doi: 10.1371/journal.pone.0010389.

Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, Kasprowicz V, Zumla A, Ndung'u T, Dheda K. Am J Respir Crit Care Med. 2010 Aug 15;182(4):569-77. 

Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. Fears R, Kaufmann S, Ter Meulen V, Zumla A; EASAC Working Group. Tuberculosis (Edinb). 2010 May;90(3):182-7. 

Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Curr Opin Pulm Med. 2010 May;16(3):262-70. 

Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A. PLoS One. 2010 Mar 24;5(3):e9848. 

Thoracic empyema: current opinions in medical and surgical management. Lee SF, Lawrence D, Booth H, Morris-Jones S, Macrae B, Zumla A. Curr Opin Pulm Med. 2010 May;16(3):194-200. 

Trials and tribulations of an African-led research and capacity development programme: the case for EDCTP investments. Zumla A, Huggett J, Dheda K, Green C, Kapata N, Mwaba P. Trop Med Int Health. 2010 Apr;15(4):489-94. 

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K. BMC Pulm Med. 2010 Feb 22;10:7. 

The relentless and persistent global threat of a range of pulmonary infections. Zumla A. Curr Opin Pulm Med. 2010 May;16(3):169-70.

Comparison of same day versus delayed enumeration of TB-specific T cell responses. Lenders LM, Meldau R, van Zyl-Smit RN, Woodburne V, Maredza A, Cashmore TJ, Semple PL, Badri M, Zumla A, Dheda K. J Infect. 2010 May;60(5):344-50. doi: 10.1016/j.jinf.2010.01.012. Epub 2010 Feb 10.

Community-based interventions to reduce maternal mortality. Ahmed Y, Mwaba P, Grange J, Green C, Zumla A. Lancet. 2010 Feb 6;375(9713):457-8; author reply 458-9. 

Biomarkers for tuberculosis disease activity, cure, and relapse. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. Lancet Infect Dis. 2010 Feb;10(2):68-9. 

Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Grange J, Adhikari M, Ahmed Y, Mwaba P, Dheda K, Hoelscher M, Zumla A. Int J Gynaecol Obstet. 2010 Mar;108(3):181-3. 

World TB Day 2010--new innovations are required for enhancing the global fight against tuberculosis: the 'captain of all these men of death'. Grange J, Mwaba P, Dheda K, Höelscher M, Zumla A. Trop Med Int Health. 2010 Mar;15(3):274-6.

Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K. nEur Respir J. 2010 Jan;35(1):27-33. 

Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Tissari P, Zumla A, Tarkka E, Mero S, Savolainen L, Vaara M, Aittakorpi A, Laakso S, Lindfors M, Piiparinen H, Mäki M, Carder C, Huggett J, Gant V. nLancet. 2010 Jan 16;375(9710):224-30.

An assessment of air as a source of DNA contamination encountered when performing PCR. Witt N, Rodger G, Vandesompele J, Benes V, Zumla A, Rook GA, Huggett JF. J Biomol Tech. 2009 Dec;20(5):236-40.

Biomarkers of disease activity, cure, and relapse in tuberculosis. Doherty TM, Wallis RS, Zumla A. Clin Chest Med. 2009 Dec;30(4):783-96, 

Tuberculosis. Preface. Zumla A, Schaaf HS. Clin Chest Med. 2009 Dec;30(4):xiii-xviii. 

Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status. Abebe M, Doherty TM, Wassie L, Aseffa A, Bobosha K, Demissie A, Zewdie M, Engers H, Andersen P, Kim L, Huggett J, Rook G, Yamuah LK, Zumla A; VACSEL study group. Eur J Immunol. 2010 Jan;40(1):291-301. 

Implications of storing urinary DNA from different populations for molecular analyses. Cannas A, Kalunga G, Green C, Calvo L, Katemangwe P, Reither K, Perkins MD, Maboko L, Hoelscher M, Talbot EA, Mwaba P, Zumla AI, Girardi E, Huggett JF; TB trDNA consortium. PLoS One. 2009 Sep 10;4(9):e6985. 

European bodies can help to tackle TB worldwide. Fears R, Zumla A, ter Meulen V. Nature. 2009 Aug 13;460(7257):796

Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI. Lancet Infect Dis. 2009 Aug;9(8):505-11. doi: 10.1016/S1473-3099(09)70149-5. Review. Erratum in: Lancet Infect Dis. 2009 Sep;9(9):536. 

Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Dheda K, van Zyl-Smit RN, Meldau R, Meldau S, Symons G, Khalfey H, Govender N, Rosu V, Sechi LA, Maredza A, Semple P, Whitelaw A, Wainwright H, Badri M, Dawson R, Bateman ED, Zumla A. Thorax. 2009 Oct;64(10):847-53

European Union conference on poverty-related diseases research. Gryseels B, Zumla A, Troye-Blomberg M, Kieny MP, Quaglio G, Holtel A, Laang H, Romaris M, De Magistris MT, Nuez AN, Olesen OF, Ghalouci R, Lönnroth A. Lancet Infect Dis. 2009 Jun;9(6):334-7. 

Biomarkers for tuberculosis disease status and diagnosis. Doherty M, Wallis RS, Zumla A; WHO-Tropical Disease Research/European Commission joint expert consultation group. Curr Opin Pulm Med. 2009 May;15(3):181-7. Review.

Utility of quantitative T-cell responses versus unstimulated interferon-{gamma} for the diagnosis of pleural tuberculosis. Dheda K, van Zyl-Smit RN, Sechi LA, Badri M, Meldau R, Meldau S, Symons G, Semple PL, Maredza A, Dawson R, Wainwright H, Whitelaw A, Vallie Y, Raubenheimer P, Bateman ED, Zumla A. Eur Respir J. 2009 Nov;34(5):1118-26. 

Editorial: emerging respiratory infections in the 21st century. Zumla A. Curr Opin Pulm Med. 2009 May;15(3):179-80. 

Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, Dheda K. Am J Respir Crit Care Med. 2009 Jul 1;180(1):49-58

Nucleic acid detection and quantification in the developing world. Huggett J, Green C, Zumla A. Biochem Soc Trans. 2009 Apr;37(Pt 2):419-23. 

Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. Dheda K, Van-Zyl Smit RN, Sechi LA, Badri M, Meldau R, Symons G, Khalfey H, Carr I, Maredza A, Dawson R, Wainright H, Whitelaw A, Bateman ED, Zumla A. PLoS One. 2009;4(3):e4689. 

Reflections on the white plague. Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. Lancet Infect Dis. 2009 Mar;9(3):197-202

Biomarkers for tuberculosis disease activity, cure, and relapse. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. Lancet Infect Dis. 2009 Mar;9(3):162-72. 

The biosocial dynamics of tuberculosis. Grange JM, Kapata N, Chanda D, Mwaba P, Zumla A. Trop Med Int Health. 2009 Feb;14(2):124-30

Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? Rook GA, Hernández-Pando R, Zumla A. J Infect Dis. 2009 Mar 1;199(5):613-8. 

BCG vaccination in children. von Reyn CF, Zumla AI. BMJ. 2008 Nov 13;337:a2086. 

Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon. Huggett JF, Novak T, Garson JA, Green C, Morris-Jones SD, Miller RF, Zumla A. BMC Res Notes. 2008 Aug 28;1:70

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A; UNZA-UCLMS Project LUCOT Collaboration. BMJ. 2008 Jul 10;337:a257. 

Gene expression of IL17 and IL23 in the lungs of patients with active tuberculosis. Dheda K, Chang JS, Lala S, Huggett JF, Zumla A, Rook GA. Thorax. 2008 Jun;63(6):566-8. 

Current opinions on selected respiratory infections causing global morbidity and mortality. Zumla A. Curr Opin Pulm Med. 2008 May;14(3):165-7. 

Tuberculosis--the tide can be turned, the battle can be won. Zumla A. J R Soc Med. 2008 Mar;101(3):100-1. 

Establishing a new service role in tuberculosis care: the tuberculosis link worker. Craig GM, Booth H, Hall J, Story A, Hayward A, Goodburn A, Zumla A. J Adv Nurs. 2008 Feb;61(4):413-24. 

Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. Wassie L, Demissie A, Aseffa A, Abebe M, Yamuah L, Tilahun H, Petros B, Rook G, Zumla A, Andersen P, Doherty TM; VACSEL Study Group. PLoS One. 2008 Jan 30;3(1):e1522. 

Steroid metabolism and immunity: therapeutic implications. Rook GA, Baker R, Zumla A. BioDrugs. 1997 Sep;8(3):157-63.

Population differences in death rates in HIV-positive patients with tuberculosis. nCiglenecki I, Glynn JR, Mwinga A, Ngwira B, Zumla A, Fine PE, Nunn A. nInt J Tuberc Lung Dis. 2007 Oct;11(10):1121-8.

The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis. Lala S, Dheda K, Chang JS, Huggett JF, Kim LU, Johnson MA, Rook GA, Keshav S, Zumla A. BMC Infect Dis. 2007 Aug 16;7:96.

Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, Novak T, Costello AM, Zumla A, Miller RF. Thorax. 2008 Feb;63(2):154-9. Epub 2007 Aug 10. Erratum in: Thorax. 2009 Jul;64(7):643. 

Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. Griffiths C, Sturdy P, Brewin P, Bothamley G, Eldridge S, Martineau A, MacDonald M, Ramsay J, Tibrewal S, Levi S, Zumla A, Feder G. Lancet. 2007 May 5;369(9572):1528-34.

FOXP3 gene expression in a tuberculosis case contact study. Burl S, Hill PC, Jeffries DJ, Holland MJ, Fox A, Lugos MD, Adegbola RA, Rook GA, Zumla A, McAdam KP, Brookes RH. Clin Exp Immunol. 2007 Jul;149(1):117-22. Epub 2007 Apr 26.

Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. Dheda K, Pooran A, Pai M, Miller RF, Lesley K, Booth HL, Scott GM, Akbar AN, Zumla A, Rook GA. J Infect. 2007 Aug;55(2):169-73. Epub 2007 Apr 19.

The impact of social factors on tuberculosis management. Craig GM, Booth H, Story A, Hayward A, Hall J, Goodburn A, Zumla A. J Adv Nurs. 2007 Jun;58(5):418-24. Epub 2007 Apr 17.

The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4delta2, is not. Dheda K, Chang JS, Huggett JF, Kim LU, Johnson MA, Zumla A, Rook GA.Tuberculosis (Edinb). 2007 May;87(3):237-41. Epub 2006 Dec 29.

Problems of developing molecular diagnostic tests for opportunistic pathogens: the example of Pneumocystis jirovecii. Huggett JF, Miller RF, Taylor MS, Costello AM, Zumla A. J Eukaryot Microbiol. 2006;53 Suppl 1:S85-6. No abstract available. 

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K, Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM; CHAP Trial Team. AIDS. 2007 Jan 2;21(1):77-84.

Expression of IL-4 mRNA in peripheral blood mononuclear cells from normal donors in relation to expression of TLR2. Chang JS, Dheda K, Huggett JF, Kim LU, Zumla A, Rook GA. Immunol Lett. 2006 Aug 15;106(2):194-7. Epub 2006 Jun 27.

The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. Demissie A, Wassie L, Abebe M, Aseffa A, Rook G, Zumla A, Andersen P, Doherty TM; VACSEL Study Group. Infect Immun. 2006 May;74(5):2817-22.

Infectious diseases. Zumla A. Curr Opin Pulm Med. 2006 May;12(3):165-6. No abstract available. 

Progress towards improved tuberculosis diagnostics for developing countries. Perkins MD, Roscigno G, Zumla A. Lancet. 2006 Mar 18;367(9514):942-3. No abstract available. 

Turning the tide against tuberculosis. Zumla A, Mullan Z. Lancet. 2006 Mar 18;367(9514):877-8. No abstract available. 

Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Rook GA, Dheda K, Zumla A. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):152-62. Epub 2006 Feb 28. Review.

Myobacterium tuberculosis induces selective up-regulation of TLRs in the mononuclear leukocytes of patients with active pulmonary tuberculosis. Chang JS, Huggett JF, Dheda K, Kim LU, Zumla A, Rook GA. J Immunol. 2006 Mar 1;176(5):3010-8.

Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM; VACSEL Study Group. Clin Vaccine Immunol. 2006 Feb;13(2):179-86.

An improved fluorescent amplified fragment length polymorphism method for typing Mycobacterium tuberculosis. Kassama Y, Shemko M, Shetty N, Fang Z, Macintire G, Gant V, Zumla A, Goodacre R. J Clin Microbiol. 2006 Jan;44(1):288-9. No abstract available. 

Treatment of tuberculosis: present status and future prospects. Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M, Grange JM. Bull World Health Organ. 2005 Nov;83(11):857-65. Epub 2005 Nov 10. Review.

Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, Zumla A, Rook GA. AIDS. 2005 Nov 18;19(17):2038-41.

BCG: the story continues. Lienhardt C, Zumla A. Lancet. 2005 Oct 22-28;366(9495):1414-6. 

Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. Dheda K, Chang JS, Breen RA, Haddock JA, Lipman MC, Kim LU, Huggett JF, Johnson MA, Rook GA, Zumla A. AIDS. 2005 Oct 14;19(15):1601-6.

Lung remodeling in pulmonary tuberculosis. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. J Infect Dis. 2005 Oct 1;192(7):1201-9. Epub 2005 Aug 29. Review.

Immune responses to tuberculosis in developing countries: implications for new vaccines. Rook GA, Dheda K, Zumla A. Nat Rev Immunol. 2005 Aug;5(8):661-7. Review.

The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, Rook GA, Zumla A. Anal Biochem. 2005 Sep 1;344(1):141-3. 

Interferon gamma assays for tuberculosis. Dheda K, Chang JS, Kim LU, Huggett JF, Johnson MA, Zumla A, Rook GA. Lancet Infect Dis. 2005 Jun;5(6):324-5; 

In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook GA, Zumla A. Am J Respir Crit Care Med. 2005 Aug 15;172(4):501-8. 

Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. Doherty TM, Demissie A, Menzies D, Andersen P, Rook G, Zumla A; VACSEL Study Group. J Immunol Methods. 2005 Mar;298(1-2):129-41.

Towards improving outcomes of fatal pulmonary infections. Zumla A. Curr Opin Pulm Med. 2005 May;11(3):187-8. No abstract available. 

Real-time RT-PCR normalisation; strategies and considerations. Huggett J, Dheda K, Bustin S, Zumla A. Genes Immun. 2005 Jun;6(4):279-84. Review.

Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Rook GA, Dheda K, Zumla A. Vaccine. 2005 Mar 18;23(17-18):2115-20. Review.

Study of familial Parkinson's disease in Russia, Uzbekistan, and Zambia. Atadzhanov M, Zumla A, Mwaba P. Postgrad Med J. 2005 Feb;81(952):117-21.

Crohn's disease and MAP. Huggett J, Dheda K, Zumla A, Rook G. Lancet. 2004 Dec 18-31;364(9452):2178; author reply 2178-9. No abstract available. 

Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Mwinga A, Chintu C, Ngwira B, Onyebujoh P, Zumla A. Int J Tuberc Lung Dis. 2004 Nov;8(11):1348-54.

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM; CHAP trial team. Lancet. 2004 Nov 20-26;364(9448):1865-71.

Smoking is not beneficial for tuberculosis. Dheda K, Johnson MA, Zumla A, Rook GA. Am J Respir Crit Care Med. 2004 Oct 1;170(7):821; author reply 821. No abstract available. 

Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9.

Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Fletcher HA, Owiafe P, Jeffries D, Hill P, Rook GA, Zumla A, Doherty TM, Brookes RH; Vacsel Study Group. Immunology. 2004 Aug;112(4):669-73.

Too hard on tropical medicine? Tomkins A, Zumla A, Pasvol G, Curtis C, Wright S. Lancet. 2004 Jul 3-9;364(9428):23. No abstract available. 

Peripheral T cell interferon-gamma responses and latent tuberculosis. Dheda K, Rook G, Zumla A. Am J Respir Crit Care Med. 2004 Jul 1;170(1):97-8; author reply 98. No abstract available. 

Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, Weldingh K, Brock I, Andersen P, Doherty TM; VACSEL Study Group. J Immunol. 2004 Jun 1;172(11):6938-43.

Type 2 cytokines in respiratory syncytial virus bronchiolitis. Dheda K, Huggett JF, Kim LU, Zumla A. Am J Respir Crit Care Med. 2004 May 15;169(10):1167-8; author reply 1168. No abstract available. 

Infectious diseases. Zumla A. Curr Opin Pulm Med. 2004 May;10(3):157-8. Review. No abstract available. 

BookPower. Zumla A, Fortescue S. Postgrad Med J. 2003 Dec;79(938):670. 

Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Mwaba P, Cassol S, Nunn A, Pilon R, Chintu C, Janes M, Zumla A. Lancet. 2003 Dec 20;362(9401):2067-8.

Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Mwaba P, Cassol S, Pilon R, Chintu C, Janes M, Nunn A, Zumla A. Lancet. 2003 Nov 1;362(9394):1459-60.

Tuberculosis: amplification-based clinical diagnostic techniques. Huggett JF, McHugh TD, Zumla A. Int J Biochem Cell Biol. 2003 Oct;35(10):1407-12. Review.

Editorial overview: Infectious diseases. Zumla AI. Curr Opin Pulm Med. 2003 May;9(3):163-5. 

The relentless spread of tuberculosis in Zambia--trends over the past 37 years (1964-2000). Mwaba P, Maboshe M, Chintu C, Squire B, Nyirenda S, Sunkutu R, Zumla A. S Afr Med J. 2003 Feb;93(2):149-52.

Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J, Zumla A; LUSKAR collaboration. Lancet. 2002 Oct 5;360(9339):1050-5.

Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F, Mwaba P, Bhat G, Terunuma H, Zumla A; UNZA-UCLMS Project Paediatric Post-mortem Study Group. Lancet. 2002 Sep 28;360(9338):985-90.

T cell receptor usage in patients with non-progressing HIV infection. Bodman-Smith MD, Williams I, Johnstone R, Boylston A, Lydyard PM, Zumla A. Clin Exp Immunol. 2002 Oct;130(1):115-20.

Evaluation of PCR-based methods for the diagnosis of tuberculosis by identification of mycobacterial DNA in urine samples. Kafwabulula M, Ahmed K, Nagatake T, Gotoh J, Mitarai S, Oizumi K, Zumla A. Int J Tuberc Lung Dis. 2002 Aug;6(8):732-7.

The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Gandy M, Zumla A. Soc Sci Med. 2002 Aug;55(3):385-96; discussion 397-401.

The global emergency of tuberculosis: what is the cause? Grange JM, Zumla A. J R Soc Promot Health. 2002 Jun;122(2):78-81.

Drugs for neglected diseases. Zumla A. Lancet Infect Dis. 2002 Jul;2(7):393. No abstract available. 

Non-tuberculous mycobacterial pulmonary infections. Zumla AI, Grange J. Clin Chest Med. 2002 Jun;23(2):369-76. Review.

Immunologic aspects of tropical lung disease. Zumla AI, James DG. Clin Chest Med. 2002 Jun;23(2):283-308, vii. Review.

Ethics of healthcare research in developing countries. Zumla A, Costello A. J R Soc Med. 2002 Jun;95(6):275-6. No abstract available. 

Infection and disease caused by environmental mycobacteria. Zumla A, Grange J. Curr Opin Pulm Med. 2002 May;8(3):166-72. Review.

Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses. Kasolo F, Lishimpi K, Chintu C, Mwaba P, Mudenda V, Maswahu D, Terunuma H, Fletcher H, Nunn A, Lucas S, Zumla A. J Pediatr. 2002 Mar;140(3):367-9.

Identification of Pneumocystis carinii DNA in oropharyngeal mouth washes from AIDS children dying of respiratory illnesses. Lishimpi K, Kasolo F, Chintu C, Mwaba P, Mudenda V, Maswahu D, Terunuma H, Fletcher H, Nunn A, Lucas S, Zumla A. AIDS. 2002 Apr 12;16(6):932-4.

Multidrug-resistant tuberculosis--can the tide be turned? Zumla A, Grange JM. Lancet Infect Dis. 2001 Oct;1(3):199-202. Review.

Hydatid disease. Ustianowski AP, Zumla A. Clin Microbiol Infect. 1998 Jul;4(7):405-409. No abstract available. 

Unique TCR beta-subunit variable gene haplotypes in Africans. Donaldson IJ, Shefta J, Lawson CA, Bushnell JR, Morgan AW, Isaacs JD, Carpenter D, Shaw MA, Rooth I, Quinnell RJ, Zumla AM, Ollier WR, Chintu CZ, Muyinda GP, Hill AS, Boylston AW. Immunogenetics. 2002 Feb;53(10-11):884-93. Epub 2002 Feb 1.

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A. Postgrad Med J. 2001 Dec;77(914):769-73.

Tuberculosis in disadvantaged groups. Grange J, Story A, Zumla A. Curr Opin Pulm Med. 2001 May;7(3):160-4. Review. 

Advances in the immunopathogenesis of pulmonary tuberculosis. Rook GA, Zumla A. Curr Opin Pulm Med. 2001 May;7(3):116-23. 

Necropsies in African children: consent dilemmas for parents and guardians. Lishimpi K, Chintu C, Lucas S, Mudenda V, Kaluwaji J, Story A, Maswahu D, Bhat G, Nunn AJ, Zumla A. Arch Dis Child. 2001 Jun;84(6):463-7.

Historical declines in tuberculosis: nature, nurture and the biosocial model. Grange JM, Gandy M, Farmer P, Zumla A. Int J Tuberc Lung Dis. 2001 Mar;5(3):208-12.

Local regulation of glucocorticoid activity in sites of inflammation. Insights from the study of tuberculosis. Rook G, Baker R, Walker B, Honour J, Jessop D, Hernandez-Pando R, Arriaga K, Shaw R, Zumla A, Lightman S. Ann N Y Acad Sci. 2000;917:913-22.

Predominance of one T-cell antigen receptor BV haplotype in African populations. Craddock TP, Zumla AM, Ollier WE, Chintu CZ, Muyinda GP, Lancaster FC, Boylston AW. Immunogenetics. 2000 Mar;51(3):231-7.

Increased cortisol: cortisone ratio in acute pulmonary tuberculosis. Baker RW, Walker BR, Shaw RJ, Honour JW, Jessop DS, Lightman SL, Zumla A, Rook GA. Am J Respir Crit Care Med. 2000 Nov;162(5):1641-7.

Moving to research partnerships in developing countries. Costello A, Zumla A. BMJ. 2000 Sep 30;321(7264):827-9. 

Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, Habbema JD, Tosteson AN, Morin P, Tvaroha S, Arbeit RD, Mwinga A, von Reyn CF. Clin Infect Dis. 2000 Jun;30 Suppl 3:S309-15.

Four-year study of abdominal ultrasound in 900 Central African adults with AIDS referred for diagnostic imaging. Tshibwabwa ET, Mwaba P, Bogle-Taylor J, Zumla A. Abdom Imaging. 2000 May-Jun;25(3):290-6.

Advances in the management of tuberculosis: clinical trials and beyond. Grange JM, Zumla A. Curr Opin Pulm Med. 2000 May;6(3):193-7. Review.

Referral times of Vietnamese refugees with tuberculosis in camps in Hong Kong. Taylor WR, Zumla A. Int J Tuberc Lung Dis. 2000 Apr;4(4):350-5.

Impact of HIV infection on tuberculosis. Zumla A, Malon P, Henderson J, Grange JM. Postgrad Med J. 2000 May;76(895):259-68. 

A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A. Int J Tuberc Lung Dis. 1999 Aug;3(8):675-80.

Paradox of the global emergency of tuberculosis. Grange JM, Zumla A. Lancet. 1999 Mar 20;353(9157):996. No abstract available. 

The tuberculosis pandemic: implications for health in the tropics. Zumla A, Squire SB, Chintu C, Grange JM. Trans R Soc Trop Med Hyg. 1999 Mar-Apr;93(2):113-7.

Protection from Pneumocystis carinii pneumonia. Day JH, Williams IG, Zumla A, Miller RF. Sex Transm Infect. 1999 Jun;75(3):202-3. No abstract available. 

Tuberculosis and the poverty-disease cycle. Grange J, Zumla A. J R Soc Med. 1999 Mar;92(3):105-7. No abstract available. 

The tuberculosis pandemic--which way now? Zumla A, Mwaba P, Squire SB, Grange JM. J Infect. 1999 Mar;38(2):74-9. Review. No abstract available. 

Doing something about tuberculosis. Zumla A, Grange JM. BMJ. 1999 Apr 10;318(7189):956.

The effects of BCG immunization and human immunodeficiency virus infection on dual skin test reactions to purified protein derivative and Mycobacterium avium sensitin among adults in Zambia. Waddell RD, von Reyn CF, Baboo KS, Mwinga A, Chintu C, Zumla A. Int J Tuberc Lung Dis. 1999 Mar;3(3):255-60.

HIV-1 seroprevalence in Zambian patients with acute diarrhea: a community-based study. Baboo KS, Luo NP, Murphy JR, Cummings C, Chintu C, Ustianowski A, DuPont HL, Kelinowski M, Mathewson JJ, Zumla A. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Feb 1;20(2):160-3.

Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia. Luo N, Perera C, Holton J, Ayles H, Zumla A. J Infect. 1998 Mar;36(2):141-3.

Is the Gulf War syndrome an immunologically mediated phenomenon? Rook GA, Zumla A. Hosp Med. 1998 Jan;59(1):10-1. No abstract available. 

Human immunodeficiency virus-associated diarrhea and wasting in Zambia: selected risk factors and clinical associations. Chintu C, Dupont HL, Kaile T, Mahmoud M, Marani S, Baboo KS, Mwansa W, Sakala-Kazembe F, Sunkutu R, Zumla A. Am J Trop Med Hyg. 1998 Jul;59(1):38-41.

Tuberculosis. Zumla A, Grange J. BMJ. 1998 Jun 27;316(7149):1962-4. Review. 

Galloping consumption. Zumla A, Grange J. Nurs Times. 1998 Apr 8-14;94(14):14. 

Establishing a united front against the injustice of tuberculosis. Zumla A, Grange JM. Int J Tuberc Lung Dis. 1998 Mar;2(3):179-81. No abstract available. 

Tuberculosis--an epidemic of injustice. Grange J, Zumla A. J R Coll Physicians Lond. 1997 Nov-Dec;31(6):637-9. No abstract available. 

Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three Central African Hospitals. Tshibwabwa-Tumba E, Mwinga A, Pobee JO, Zumla A. Clin Radiol. 1997 Nov;52(11):837-41.

Nosocomial transmission of tuberculosis in HIV/AIDS units in London. De Cock KM, Miller R, Zumla A, Holton J, Williams I. Genitourin Med. 1997 Aug;73(4):322. 

Making DOTS succeed. Directly Observed Treatment, Short Course. Grange JM, Zumla A. Lancet. 1997 Jul 19;350(9072):157. 

Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Rook GA, Zumla A. Lancet. 1997 Jun 21;349(9068):1831-3.

Adrenal function and the hypothalamo-pituitary adrenal axis in immunodeficiency virus-associated tuberculosis. Baker R, Rook GA, Zumla A. Int J Tuberc Lung Dis. 1997 Jun;1(3):289-90. No abstract available. 

Granulomatous infections: etiology and classification. Zumla A, James DG. Clin Infect Dis. 1996 Jul;23(1):146-58. Review.

Isolation of Campylobacter species from Zambian patients with acute diarrhoea. Luo NP, Baboo KS, Mwenya D, Diab A, Perera CU, Cummings C, Dupont HL, Murphy JR, Zumla A. East Afr Med J. 1996 Jun;73(6):395-6.

The spectrum of African Kaposi's sarcoma: is it consequential upon diverse immunological responses? Matondo P, Zumla A. Scand J Infect Dis. 1996;28(3):225-30. Review.

Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia. Chintu C, Luo C, Bhat G, DuPont HL, Mwansa-Salamu P, Kabika M, Zumla A. J Trop Pediatr. 1995 Dec;41(6):348-53.

Pattern of adult malignancies in Zambia (1980-1989) in light of the human immunodeficiency virus type 1 epidemic. Patil P, Elem B, Zumla A. J Trop Med Hyg. 1995 Aug;98(4):281-4.

HEp-2 cell-adherent Escherichia coli in patients with human immunodeficiency virus-associated diarrhea. Mathewson JJ, Jiang ZD, Zumla A, Chintu C, Luo N, Calamari SR, Genta RM, Steephen A, Schwartz P, DuPont HL. J Infect Dis. 1995 Jun;171(6):1636-9.

Parasites and HIV-related diarrhoea. Zumla A, Chintu C. S Afr Med J. 1995 Jun;85(6):494-5. 

Intestinal parasites in HIV-seropositive Zambian children with diarrhoea. Chintu C, Luo C, Baboo S, Khumalo-Ngwenya B, Mathewson J, DuPont HL, Zumla A. J Trop Pediatr. 1995 Jun;41(3):149-52.

Use of saliva as an alternative to serum for HIV screening in Africa. Luo N, Kasolo F, Ngwenya BK, du Pont HL, Zumla A. S Afr Med J. 1995 Mar;85(3):156-7.

Childhood tuberculosis and infection with the human immunodeficiency virus. Chintu C, Zumla A. J R Coll Physicians Lond. 1995 Mar-Apr;29(2):92-5. Review.

Gut parasites in HIV-seropositive Zambian adults with diarrhoea. Khumalo-Ngwenya B, Luo NP, Chintu C, Sunkutu R, Sakala-Kazembe F, Baboo KS, Mathewson J, Zumla A. East Afr Med J. 1994 Jun;71(6):379-83.

Common childhood illnesses and HIV infection in Africa. Zumla A, Chintu C, Luo C. S Afr Med J. 1994 May;84(5):296,298. No abstract available. 

Tuberculosis and HIV infection. Zumla A, Chintu C. Lancet. 1994 Apr 2;343(8901):851-2. No abstract available. 

Association of rotavirus and human immunodeficiency virus infection in children hospitalized with acute diarrhea, Lusaka, Zambia. Oshitani H, Kasolo FC, Mpabalwani M, Luo NP, Matsubayashi N, Bhat GH, Suzuki H, Numazaki Y, Zumla A, DuPont HL. J Infect Dis. 1994 Apr;169(4):897-900.

Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen. Luo C, Chintu C, Bhat G, Raviglione M, Diwan V, DuPont HL, Zumla A. Tuber Lung Dis. 1994 Apr;75(2):110-5.

Intestinal secretory IgA immune response against human immunodeficiency virus among infected patients with acute and chronic diarrhea. Mathewson JJ, Jiang ZD, DuPont HL, Chintu C, Luo N, Zumla A. J Infect Dis. 1994 Mar;169(3):614-7.

AIDS case definitions in developing countries. Chintu C, Zumla A. Lancet. 1993 Oct 23;342(8878):1054-5. 

Anti-bovine viral diarrhoea virus antibodies in adult Zambian patients infected with the human immunodeficiency virus. Giangaspero M, Vacirca G, Morgan D, Baboo KS, Luo NP, DuPont HL, Zumla A. Int J STD AIDS. 1993 Sep-Oct;4(5):300-2.

Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Chintu C, Bhat G, Luo C, Raviglione M, Diwan V, Dupont HL, Zumla A. Pediatr Infect Dis J. 1993 Jun;12(6):499-504.

Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A. Arch Dis Child. 1993 May;68(5):665-8.

Case definitions for paediatric AIDS: the Zambian experience. Chintu C, Malek A, Nyumbu M, Luo C, Masona J, DuPont HL, Zumla A. Int J STD AIDS. 1993 Mar-Apr;4(2):83-5.

Use of a murine T-cell hybridoma expressing human T-cell receptor alpha- and beta-gene products as a tool for the production of human T-cell receptor-specific monoclonal antibodies. Zumla A, McCormack A, George A, Batchelor R, Lechler R. Hum Immunol. 1992 Nov;35(3):141-8.

Superantigens--progress in understanding microbial pathogenesis. Zumla A, van den Bogaerde J. S Afr Med J. 1992 Sep;82(3):146-8. 

Superantigens, T cells, and microbes. Zumla A. Clin Infect Dis. 1992 Aug;15(2):313-20. Review.

Co-expression of human T cell receptor chains with mouse CD3 on the cell surface of a mouse T cell hybridoma. Zumla A, Marguerie C, So A, Yokoyama WM, Saito T, Batchelor JR, Lechler RI. J Immunol Methods. 1992 Apr 27;149(1):69-76.

Chloroquine and proguanil prophylaxis in travellers to Kenya. Zumla A. Lancet. 1992 Jan 4;339(8784):62-3. 

Chemotherapy and immunity in opportunistic parasitic infections in AIDS. Zumla A, Croft SL. Parasitology. 1992;105 Suppl:S93-101. Review..

T cell receptor expression in Sjögren's syndrome. Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D. Ann Rheum Dis. 1991 Oct;50(10):691-3.

Mimics of sarcoidosis. Leprosy. Zumla A. Sarcoidosis. 1991 Sep;8(2):89-94. No abstract available. 

Salmonella septic arthritis. Luo NP, Perera CU, Zumla A. J Infect. 1991 Jul;23(1):101. No abstract available. 

Expression of a common idiotype PR4 in the sera of patients with leprosy. Zumla A, Williams W, Mudd D, Locniskar M, Behrens R, Isenberg D, McAdam KP. Clin Exp Immunol. 1991 Jun;84(3):522-6.

Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus. Zumla A, Savva D, Wheeler RB, Hira SK, Luo NP, Kaleebu P, Sempala SK, Johnson JD, Holliman R. Trans R Soc Trop Med Hyg. 1991 Mar-Apr;85(2):227-9.

Surgery and Salmonella. Zumla A, Luo NP. BMJ. 1990 May 19;300(6735):1342. No abstract available. 

Autoantibodies and tropical infections. Zumla A. Trans R Soc Trop Med Hyg. 1990 Jan-Feb;84(1):162-5. Review.

Topical zoonosis. Zumla A. J Infect. 1989 Nov;19(3):291. No abstract available. 

Dysgonic fermenter type 2 infection. Zumla A. Lancet. 1989 Sep 9;2(8663):627. No abstract available. 

Sarcoidosis and leprosy--an epidemiological, clinical, pathological and immunological comparison. Zumla A, James GD. Sarcoidosis. 1989 Sep;6(2):88-96. Review.

Malaria in spite of chemoprophylaxis. Lulat A, Zumla A. J Infect. 1989 Sep;19(2):186-7. No abstract available. 

Honey--a remedy rediscovered. Zumla A, Lulat A. J R Soc Med. 1989 Jul;82(7):384-5. Review. No abstract available. 

Spontaneous subcapsular splenic haematoma formation in infectious mononucleosis. Brown J, Marchant B, Zumla A. Postgrad Med J. 1989 Jun;65(764):427-8. No abstract available. 

Purpura and sepsis--rarer causes? Zumla A, Lipscomb G. Br J Dermatol. 1989 May;120(5):715-6.

Malaria prophylaxis--a persisting dilemma. Zumla A, Laurenson I. J Antimicrob Chemother. 1989 May;23(5):809-10. No abstract available. 

DF-2 infection. McCarthy M, Zumla A. BMJ. 1988 Nov 26;297(6660):1355-6. Review. No abstract available. 

Sixth cranial nerve palsy complicating psittacosis. Zumla A, Lipscomb G, Lewis D. J Neurol Neurosurg Psychiatry. 1988 Nov;51(11):1462. No abstract available. 

Dysgonic Fermenter-type 2: an emerging zoonosis. Report of two cases and review. Zumla A, Lipscomb G, Corbett M, McCarthy M. Q J Med. 1988 Sep;68(257):741-52. Review.

Studies of a common idiotype PR4 in autoimmune rheumatic disease. Williams W, Zumla A, Behrens R, Locniskar M, Voller A, McAdam KP, Isenberg DA. Arthritis Rheum. 1988 Sep;31(9):1097-104.

Legionnaires' disease: early lessons from 1988 London outbreak. Zumla A, Weyell R, Tettmar RE. Lancet. 1988 Jun 4;1(8597):1275. No abstract available. 

Human monoclonal antibodies to phenolic glycolipid-I derived from patients with leprosy, and production of specific anti-idiotypes. Locniskar M, Zumla A, Mudd DW, Isenberg DA, Williams W, McAdam KP. Immunology. 1988 Jun;64(2):245-51.

Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a splenectomized and immunosuppressed patient. Zumla A, Lewis D, Brown J. J Antimicrob Chemother. 1988 Jun;21(6):809-10. 

Human monoclonal antibodies to phenolic glycolipid-1 from leprosy patients cross react with poly(ADP-ribose), polynucleotides and tissue bound antigens. Zumla A, Williams W, Shall S, Locniskar M, Leigh I, McAdam KP, Isenberg D. Autoimmunity. 1988;1(3):183-95.

A serological study on primary hepatocellular carcinoma in Zambia. Zumla A, Voller A. Trans R Soc Trop Med Hyg. 1982;76(4):546-51.